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The article contains raw and analyzed data related to the research
article “Neuronal ceroid lipofuscinosis genes, CLN2, CLN3, CLN5
are spatially and temporally co-expressed in a developing mouse
brain” (Fabritius et al., 2014) [1]. The processed data gives an
understanding of the development of the cell types that are
mostly affected by defective function of CLN proteins, timing of
expression of CLN1, CLN2, CLN3 and CLN5 genes in a murine
model. The data shows relationship between the expression
pattern of these genes during neural development. Immunohis-
tochemistry was used to identify known interneuronal markers
for neurotransmission and cell proliferation: parvalbumin,
somatostatin subpopulations of interneurons. Non-radioactive in-
situ hybridization detected CLN5 mRNA in the hippocampus.
Throughout the development strong expression of CLN genes










H.M. Minye et al. / Data in Brief 8 (2016) 741–749742regions, cortex, hippocampus, and cerebellum. This provides
supportive evidence that CLN1, CLN2, CLN3 and CLN5 genes may
be involved in synaptic pruning.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications Tableubject area Molecular Biology, Molecular Pathology
ore specific sub-
ject areaMolecular Genetics, Molecular Medicine, Neurogenetics, Neurogenesisype of data Images, microscopy, figures
ow data was
acquiredMicroscopy, immunohistochemistry, molecular biology, murine models, non-
radioactive in-situ hybridization.ata format Raw, analyzed
xperimental
factorsFor in-situ analyses, sectioned, fixation in 4% paraformaldehyde. For immu-
nohistochemistry, brains and embryos were post-fixed in 4% PFA, embedded
in paraffin.xperimental
featuresThe timing of genetic expression of CLN1, CLN2, CLN3 and CLN5 genes were
investigated during brain development. Tested murine model with known
interneuronal markers using immunohistochemistry.ata source
locationLos Angeles, California, United States. Geographic coordinates 34.0722°N,
118.4441°Wata accessibility Within the Data in Brief article.D
Value of the data
 CLN 2, CLN3, CLN5 genes are expressed in the glia, hippocampus, cerebellum, and ventricles in a
murine model can be functionally categorized.
 Specific evidence of genetic expression of CLN2, CLN3, CLN5 give insights to the selective neuro-
degeneration known in the disease.
 CLN1, CLN2, CLN3 and CLN5 gene expression profiles play an important role in early embryonal
neurogenesis; may stimulate further research in their role in neuronal differentiation, neuroplas-
ticity, and synaptic pruning.1. Data
Neuronal ceroid lipofuscinosis genes: CLN1, CLN2, CLN3, CLN5 were examined in neuronal tissue
during mouse brain development. Interneuronal subpopulations immunoreactive to parvalbumin and
somatostatin were identified to be co-expressed with CLN1, CLN2, CLN3, CLN5 proteins in the post-
natal cortex and hippocampus.2. Experimental design, materials and methods
2.1. Tissue preparation
Brains and embryos were obtained from mouse strain C57 BL/6J on embryonic days E18.5 and
postnatal days P24 and P60. The morning of the vaginal plug was defined as embryonic day 0.5 (E0.5)
H.M. Minye et al. / Data in Brief 8 (2016) 741–749 743and the day of birth as P0. Animals were maintained in specific pathogen-free conditions according to
the regulations of the Department of Laboratory Animal Medicine at the University of California, Los
Angeles. Animals were anesthetized of animals was performed with 0.04 ml of ketamine HCl (25 mg/
ml, Ketaject, Phoenix Scientific, Inc., St. Joseph, MD, USA) after which they were sacrificed by cervical
dislocation. For immunohistochemistry, older animals (P24 and P60) were intracardially perfused
with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffered saline (PBS) before removal of the brain
[1]. All procedures were performed according to institutional and NIH guidelines (Figs. 1–5).
2.2. Reverse transcription
CLN5 RNA was isolated from mouse brain tissue RT-PCR was converted to cDNA with 9961(1:30)
primers: 30CACTGGAAGGAAAACGGGACA 50 and S5513A04 (1:10): 50 GGGCCCAAAGGAAACAAG 30 and
9960 (1:30) primer using Superscript reverse transcriptase and 10 dNTPs incubated at 45 °C forFig. 1. CLN2, CLN3, and CLN5 expression in the hippocampus, cortex and cerebellum in P24. 1-1: Immunodetection of CLN2 in
hippocampus. 1-2: Immunodetection of CLN2 in cortex. 1-3: Immunodetection of CLN2 in Purkinjie cells. 1-4: Immunode-
tection of CLN3 in hippocampus. 1-5 Immunodetection of CLN3 in cortex. 1-6: Immunodetection of CLN3 in Purkinjie cells. 1-7:
Immunodetection of CLN5 in hippocampus. 1-8: Immunodetection of CLN5 in cortex. 1-9: Immunodetection of CLN5 in Pur-
kinjie cells. CLN3 and CLN5 proteins were strongly expressed in the inner migratory zone. Positive signaling is indicative by the
brown stain, blue is the counterstain.
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Polymerase and reamplified Taq DNA polymerase (Amersham Pharmacia Biotech). The DNA template
was then purified with Qiaquick PCR purification to remove the enzymes, excess dNTPs and poly-
merases, and salts.Fig. 2. Expression pattern of CLN5 in developing E18.5 hippocampus and cerebellum. 2-1: Hippocampus layers, CA1 and CA2.
2-2: Magnified view [100 ] of pyramidal cells in selected region of 1. Positive signaling is indicative by the brown stain, blue is
the counterstain. 2-3: Developing cerebellum, 2-4: Magnified view [100 ] of the developing cerebellum. 2-5: Magnified
[400 ] Purkinjie cell layer stained with CLN5 antibody in embryonic cerebellum.
Fig. 3. 3-1: CLN5 protein detected in the axon and dendrites of neurons in the cortex in P24 mouse brain. 3-2: Intense
immunopositivity of CLN5 protein in the cytoplasm of interneurons in pons in P24 mouse brain. Positive signaling is indicative
by the brown stain, blue is the counterstain.
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Escherichia coli cells were transformed using pGEM-T Easy Vector that contains a T7 and SP6 promoter
on each end of the MCS (Promega). Using 2.5 ml of DNA template obtained as PCR product and T4 DNA
Ligase (3 Weiss units/ml) were used for a total reaction of 10 ml. Cells went through heat shock stress and
screened using IPTG and Lac Z expression after plating on LB and 50 mg/ml Ampicillin overnight at 4 °C for
four of the six ligations and at 37 °C for the remaining two. Transformants were isolated using blue/white
screening. Single colonies were inoculated in LB-ampmedia at 37 °C. To determine whether the insert was
cloned, the insert was removed using NotI cleavage from the plasmid and run on a 1% high melt agarose
gel. Plasmids were recovered by maxiprep (Qiagen).
2.4. Sequencing
DNA was precipitated by ethanol treatments and sodium acetate pH 4.6. BigDye was used
sequencing to determine if both sense and antisense strands have be cloned as well as the orientationFig. 4. CLN1, CLN2, CLN3, CLN5 expressed in parvalbumin and somatostatin subpopulations of interneurons in P60 mouse
cortex. 4-A: CLN2 immunopositivity in parvalbumin-type interneurons. 4-B: CLN3 immunopositivity in parvalbumin-type
interneurons. 4-C: CLN5 immunopositivity in parvalbumin-type interneurons.4-D: CLN2 immunopositivity in somatostatin-
type interneurons. 4-E: CLN3 immunopositivity in somatostatin-type interneurons. 4-F: CLN5 immunopositivity in somatos-
tatin-type interneurons. 4-G: CLN1 immunopositivity in parvalbumin-type interneurons. 4-H: CLN1 immunopositivity in
somatostatin-type interneurons. Positive signaling is indicative by the brown stain, blue is the counterstain.
Fig. 5. Immunopositive for reactivity of CLN2, CLN3, CLN5 in somatostatin subpopulation of interneurons in the hippocampus
in P24. 5-A, B, C: CLN2 expressed in somatostatin positive cells in the hippocampus. 5-D, E, F: CLN3 expressed in somatostatin
positive cells in the hippocampus. 5-G, H, I: CLN5 expressed in somatostatin positive cells in the hippocampus. Positive sig-
naling is indicative by the brown stain, blue is the counterstain.
H.M. Minye et al. / Data in Brief 8 (2016) 741–749746at insertion in the plasmid. Single restriction digest with EcoRI was not useful in determining insert
orientation because it resided approximately in the middle of the insert (223 bp/336 bp); making the
orientation of insert as well as the sequence identifiable using Sequencher (Fig. 6).2.5. Non-radioactive probe synthesis
The plasmid was linearized with SpeI and NcoI. The SpeI digest and NcoI digested templates were
transcribed with T7 RNA polymerase and SP6 polymerase (with additional 100 mM MgCl2 added)
respectively to generate sense ssRNA and NTP mix the digoxigenin labeled uracil incorporated into
the RNA by in vitro transcription (Roche Molecular Biochemicals). RNAwas precipitated using ethanol
and 4 M lithium chloride. The RNA was quantitated using dot-blot technique on nylon membrane and
immunodetected with Anti-digoxigenin Fab fragments (Roche Molecular Biochemicals) conjugated
with alkaline phosphatase and identified with substrate, NBT/BCIP (Roche Molecular Biochemicals).
Presence of RNA was also confirmed on a 1% high melt agarose gel.
Fig. 6. CLN 5 expression of RNA antisense DIG-labeled transcripts in the longitudinal section of the P60 hippocampus. 6A:
mRNA expression of CLN5 in mouse brain at 60 days can be observed in the hippocampus. 6B: Magnified [100 ] mRNA
expression of CLN5 in mouse brain at postnatal 60 days. 6C: Magnified [400 ] mRNA expression of CLN5 in mouse brain at
postnatal 60 days. 6D: Negative control for specificity of the CLN5 probe.
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Brain sections at varying stages of development were sectioned in paraffin. Sections were washed
with glycine in 0.1 M phosphate buffer, 0.1 M phosphate buffer, followed by 0.25% acetic anhydride in
0.1 triethanolamine (TEA) pH 8.0, and dehydrated using ethanol and chloroform. Hybridization pre-
paration included 300 mg/ml salmon sperm, 15 mg/ml tRNA, 40 mM DTT, and digoxgenin labeled
probe diluted in hybridization buffer and incubated at 60 °C overnight with DPX mountant. The sense
and antisense transcripts were then washed with decreasing SSC concentration and blocked with
0.05 g BSA/10TBS at 37 °C. Section were incubated with 1:500 Anti-digoxigenin Fab fragments
(Roche Molecular Biochemicals) in 4 °C conjugated with alkaline phosphatase and identified with
substrate, NBT/BCIP (Roche Molecular Biochemicals) in detection buffer pH 9.5. Then dehydrated with
ethanol and HemoD (Fig. 6).
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templates for the probes for in situ hybridization were generated from mouse brain total RNA by
reverse transcriptase (RT)-PCR amplification (Invitrogen, Carlsbad, CA). CLN2 probe was synthesized
using a CLN2-specific sense primer (nucleotides 575–593 in mouse cDNA) and an antisense primer
(nucleotides 878–856 in mouse cDNA). CLN3 probe was obtained using a CLN3-specific sense primer
(nucleotides 40–60 in mouse cDNA) and an antisense primer (nucleotides 370–349 in mouse cDNA).
CLN5 probe was amplified from mouse cDNA that corresponded nucleotides 1606–1803 in human
CLN5 cDNA. Primers used for amplification of CLN5 were 50-TACAAGCGCTTCTCTTTCCGTC-30 (sense-
primer) an ATCCCACGGCGTCATGCATAAGTTT-30 (antisense-primer) [7]. PCR-amplified cDNA frag-
ments were cloned into pGemT-Easy (Promega, Madison, WI). Images were taken with Olympus
digital camera and minimally processed in Adobe Photoshop Elements program (Figs. 1–5).2.8. Antibodies
To obtain mouse CLN5 protein for immunization, the cDNA of mouse CLN5, corresponding to
human cDNA nucleotides 1606–2520, was cloned into a pGEX-6P-1 vector (Pharmacia, Sweden). The
CLN5 polypeptides were expressed in the E. coli strain BL21-E as a glutathione S-transferase (GST)
fusion protein and purified with Glutathione Sepharose (Pharmacia, Sweden). Rabbits were immu-
nized by subcutaneous injection with 500 μg of the CLN5 fusion protein in Freund's complete adju-
vant. Immunization was repeated four times and the blood was collected one week after the last
immunization [1]. A small sample of blood was also collected before the first immunization (i.e. pre
immune serum). The CLN2-specific antibody against amino acids 368–383 in human CLN2 and the
antibody against the mouse CLN3 peptide have been previously described [2,4–6].2.9. Immunohistochemistry
Brains and embryos were post-fixed in 4% PFA for 20 h after which they were embedded in par-
affin. The tissue was cut into 4 μm sections placed on Superfrost Plus slides. Immunohistochemical
staining: after deparaffinization with xylene and decreasing graded series of ethanol solutions,
endogenous peroxidase activity in mouse tissue sections was blocked with 3% H2O2 in methanol for
10 min. For antigen retrieval, sections were incubated in 10 mM Na-citrate buffer (pH 6.0) at 95 °C for
20 min followed by three washes (5 min each) in PBS-buffer. Unspecific binding of antibodies was
blocked by incubating sections in 3% goat normal serum (Vector, Burlingame, CA) in PBS for 30 min
after which avidin–biotin blocking was performed according to manufacturer's protocol (Vector).
Primary antibodies were diluted in 3% goat normal serum: CLN1 antibody in 1:300 [8], CLN2 antibody
in 1:500, CLN3 antibody in 1:250 and CLN5 antibody in 1:1000 dilutions. Parvalbumin-specific
antibodies (Swant 1:6000 dilution) [3] and somatostatin-specific antibodies (Swant 1:5000). Primary
antibodies were incubated for 18 h at 4 °C after which sections were washed three times for 5 min in
PBS buffer followed by incubation in secondary antibody, goat anti-rabbit antiserum (1:200), for
30 min at RT. After 35 min rinses in PBS, sections were treated with avidin-biotinylated horseradish
peroxidase complex (ABC, Vector) for 30 min at room temperature followed by three rinses in PBS
(5 min each). Binding of antibodies was detected with DAB staining kit (Vector) after which the
sections were counter stained in Harris Modified Hematoxylin (Fisher), dehydrated in increasing
series of ethanol and xylene and mounted with mounting medium (Richard Allan Scientific). Images
were captured with an Olympus microscope and a camera. As a control for specificity of immunosera,
pre-immune serum was used when available (for CLN2 and CLN5). For CLN5, as a control for
unspecific staining, blocking of antigenic sites with CLN5 protein was also used [2,7]. This was done
by incubating 5–25 times excess of CLN5 protein together with CLN5 immunosera at RT for 30 min.
This mixture was then used along the immunostaining procedure as a primary antiserum. The
incubation without the primary antibody served as a general control [1].
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